Transgene

Transgene est membre de Lyonbiopôle

General information

400 Boulevard Gonthier d'Andernach Parc d'Innovation

67405 Illkirch-Graffenstaden

Incorporated in: 1979/12/30

Number of employees: 140

Turnover: €2M (in 2016)


More information

 

Main activity

Transgene, part of Institut Mérieux, is a publicly traded French biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancers and infectious diseases. Transgene’s programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells. The Company’s lead clinical-stage programs are: TG4010 for non-small cell lung cancer, Pexa-Vec for liver cancer and TG4001 for HPV-positive head and neck cancers. The Company has several other programs in clinical and pre-clinical development. Transgene also owns Invir.IO(TM), a new technology platform dedicated to the design of the next generation of oncolytic viruses. These multifunctional viruses are aimed at modulating the tumor micro-environment. The Company is based in Strasbourg, France, and has additional operations in Lyon, in China and in the U.S.


Funding

Looking for funding: Yes

Nature of funding searches: Transgene may seek to partner its programs in oncology and ID with pharmaceutical partners as they reach key pre-clinical or clinical development milestones. The Company is also leveraging its R&D capabilities through collaborative agreements and/or grant-supported collaborative programs with external organizations.

Public funding obtained: Transgene has a strong track record of fruitful collaboration with external partners and has been involved in more than 15 grant-supported collaborative programs

Stock exchange listing: Euronext Paris (compartment B) since 1998

Segmentation
Activities
Products / Services / Technologies
Partnership opportunities / Licensing

Strategic area of application
Human Medicine


Application market
Infectiology - Parasitology - Oncology


Activities
Therapeutics, Pharma or Biotech


Technologies
Cell Therapy - cell biology - Biobanking - Vaccine - Molecular Biology and Nucleic acid

En poursuivant votre navigation sur ce site, vous acceptez l'utilisation de cookies pour vous proposer des services et offres adaptés à vos centres d'intérêt. En savoir plus... Fermer